Company intelligence / Profile preview

GeneOS

Plymouth Meeting, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Geneos Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized therapeutic cancer vaccines. The company utilizes its proprietary GT-EPIC platform to design and manufacture DNA-based neoantigen vaccines tailored to the unique genetic profile of an individual's tumor. Their lead program, GNOS-PV02, is currently being evaluated in Phase 2 clinical trials for the treatment of advanced hepatocellular carcinoma in combination with checkpoint inhibitors. By targeting a large number of patient-specific neoantigens, Geneos aims to stimulate a robust and diverse T-cell response to combat various solid tumors.

Therapeutic areas: Oncology
Modalities: DNA vaccineImmunotherapy
Industry: Biotech

Partnerships

Inovio PharmaceuticalsMerck

Beyond the preview

Go deeper on GeneOS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneOS.

Explore the full profile